Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01518374 · ClinicalTrials.gov registry record · Phase 2
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
A Phase 2 study, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,768
- Enrollment target
NCT01518374 is a Phase 2 study that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 1,768 participants.
The verdict
NCT01518374, a Phase 2 study, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,768 participants
- Enrollment target
Study Summary
This protocol is designed to standardize imaging studies using florbetapir F 18 PET to provide information on amyloid burden in subjects participating in other studies (companion protocol) such as longitudinal studies of aging and studies of biomarkers for neurodegenerative diseases.
Interventions
- DRUG Florbetapir F 18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,768 participants |
| Start Date | 2009-12 |
| Est. Completion | 2017-05-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01518374
The ClinicalTrials.gov registry entry for NCT01518374 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,768 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avid Radiopharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Florbetapir F 18 is the first listed.
NCT01518374 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01518374 about?
NCT01518374 is a clinical study titled "Clinical Evaluation of Florbetapir F 18 (18F-AV-45)". This protocol is designed to standardize imaging studies using florbetapir F 18 PET to provide information on amyloid burden in subjects participating in other studies (companion protocol) such as longitudinal studies of aging and studies of biomarkers for neurodegenerative diseases.
What is the current status of trial NCT01518374?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,768 participants. The study started on 2009-12. Estimated completion is 2017-05-03.
What interventions are being tested in trial NCT01518374?
The interventions under investigation include: Florbetapir F 18 (DRUG).
Who is sponsoring clinical trial NCT01518374?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.